4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
Condition: Epilepsy
MeSH terms: Seizures
Intervention: Perampanel
Intervention description: Perampanel 2 mg to 12 mg, once daily during the OLE study
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 138.0
Sex: All
Minimum age: 18 Years
Maximum age: 70 Years
Healthy volunteers: No
Keywords: Refractory; Partial; Seizures

Summary:

      The purpose of this study is to determine the safety of perampanel given as adjunctive,
      long-term treatment in patients with refractory partial onset seizures.
    

Eligibility criteria:

        KEY INCLUSION CRITERIA:

          1. Have completed all scheduled visits up to and including Visit 8 in the E2007-A001-206
             (NCT00144690) study or Visit 9 of the E2007-G000-208 (NCT00416195) study.

          2. Are reliable and willing to make themselves available for the study period and are
             able to record seizures and report adverse events themselves or have a caregiver who
             can record and report the events.

          3. Females of childbearing potential must continue practicing a medically acceptable
             method of contraception (e.g., abstinence, a barrier method plus spermicide, or
             Intrauterine device (IUD)) and for 8 weeks after the end of the OLE study. Those women
             using hormonal contraceptives must also continue using an additional approved method
             of contraception (e.g., a barrier method plus spermicide, or IUD).

          4. Are between the ages of 18 and 70 years of age, inclusive.

          5. Are at least 40 kg (88 lb) of weight.

          6. Are currently being treated with a stable dose of one, or a maximum of three licensed
             Anti-epileptic drugs (AEDs) and are known to take their medication(s) as directed.

        KEY EXCLUSION CRITERIA:

          1. Show evidence of clinically significant disease (cardiac, respiratory,
             gastrointestinal, renal disease, etc.,) that, in the opinion of the Investigator(s),
             could affect the participant's safety or trial conduct.

          2. Show evidence of significant active hepatic disease and/or bilirubin greater than 1.5
             mg/dL. Stable elevations of liver enzymes, alanine aminotransferase (ALT), and
             aspartate aminotransferase (AST) due to concomitant medication(s) will be allowed if
             they are less than two times the upper limit of normal (ULN).

          3. Show evidence of significant active hematological disease. White blood cell (WBC)
             count cannot be less than or equal to 2500/microL or an absolute neutrophil count less
             than or equal to 1000/microL.

          4. Clinically significant ECG abnormality, including prolonged QTc (defined as greater
             than or equal to 450 msec).

          5. Presence of major active psychiatric disease. Participants taking a stable dose of
             selective serotonin reuptake inhibitor (SSRI) antidepressant will be allowed.